Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 2/20 | 0.51 |
| ▸ | TOP1 | P11387 | 1/20 | 0.32 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29501639 | 1.00 | DRD1 (0.51) | DRD1TOP1STING1ALDH1A1HPGD | |
| SCHEMBL21111890 | 0.92 | DRD1 (0.50) | DRD1 | |
| SCHEMBL708320 | 0.90 | DRD1 (0.61) | DRD1 | |
| SCHEMBL31758911 | 0.89 | DRD1 (0.49) | DRD1ALDH1A1HPGDLTA4HMAPT | |
| SCHEMBL29501652 | 0.86 | DRD1 (0.55) | DRD1 | |
| SCHEMBL21111854 | 0.86 | DRD1 (0.55) | DRD1 | |
| SCHEMBL29501658 | 0.86 | DRD1 (0.55) | DRD1 | |
| SCHEMBL668454 | 0.86 | ALDH1A1 (0.39) | DRD1ALDH1A1HPGDMAPT | |
| SCHEMBL21111784 | 0.86 | DRD1 (0.51) | DRD1 | |
| SCHEMBL29501684 | 0.86 | DRD1 (0.51) | DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919921-B2 | P-chiral phosphine ligands and use thereof for asymmetric synthesis | BASF SE | 2021-02-16 | — | — | US | disclosed |
| US-20190211040-A1 | P-CHIRAL PHOSPHINE LIGANDS AND USE THEREOF FOR ASYMMETRIC SYNTHESIS | BASF SE (DE) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190211040-A1 | P-CHIRAL PHOSPHINE LIGANDS AND USE THEREOF FOR ASYMMETRIC SYNTHESIS | PLCD1, PLCB3, PHOSPHO1 | DRD1 2508/4885TOP1 3233/4885STING1 2763/4885 |
| US-10919921-B2 | P-chiral phosphine ligands and use thereof for asymmetric synthesis | PLCD1, PLCB3, PHOSPHO1 | DRD1 2508/4885TOP1 3233/4885STING1 2763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.